Lynparza On Track For Broad Frontline Use In Prostate Cancer

Leading PARP Inhibitor’s Uses Keep Expanding

 
• By Andrew McConaghie
  
AstraZeneca
Lynparza is one of a handful of targeted cancer therapies currently leading AstraZeneca's growth. • Source: Shutterstock: Elzbieta Krzysztof
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip